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The mechanisms underlying the increased risk of cardiovascular disease associated with diabetes mellitus (DM) are not fully
defined. Insulin resistance in human metabolic syndrome patients is associated with decreased expression of the insulin receptor
substrate-2- (Irs2-) AKT2 axis in mononuclear leukocytes (MLs). Moreover, acute coronary syndrome (ACS) has been linked
through genome-wide association studies to the 2q36-q37.3 locus, which contains the Irs1 gene. Here, we investigated the
expression of insulin-signaling pathway genes in MLs from patients with DM, ACS, and ACS plus DM. Quantitative real-time
PCR expression studies showed no diﬀerences in the mRNA levels of Irs2, Akt2, and Akt1 among all patients. However, Irs1 mRNA
expression was significantly increased in patients with ACS—diabetics and nondiabetics—compared with diabetic patients without
ACS (P < .02 and P < .005, resp.). The present study reveals for the first time an association between increased Irs1 mRNA levels
in MLs of patients with ACS which is not related to DM.
1. Introduction
The risk of cardiovascular disease (CVD) and atherosclerosis
is 2–5 times higher in patients with diabetes mellitus (DM).
Indeed, most DM patients die from CVD complications,
mainly myocardial infarction and stroke [1–3]. The preva-
lence of DM is expected to increase significantly in the next
40 years as a consequence of population aging and the adop-
tion of sedentary lifestyle patterns and is thus set to become
a social and health care burden [4]. It is therefore important
to understand the molecular mechanisms underlying the
acceleration of CVD in DM, in order to identify novel
markers and develop preventive and therapeutic strategies.
Insulin resistance (IR) in patients with metabolic syn-
drome (MetS), who are at high cardiovascular risk, is
associated with impaired insulin signaling via the insulin
receptor substrate-2- (Irs2-) AKT2 pathway in mononuclear
leukocytes (MLs) [5]. In mice, deficiency for the Irs2 gene
produces MetS [6–8], and partial or total inactivation of Irs2
aggravates atheroma development in the apolipoprotein E-
null (apoE−/−) mouse model of atherosclerosis [5, 9, 10].
Consistent with the human studies, partial ablation of Irs2
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in apoE−/− mice also reduces IRS2/AKT2 and Ras/ERK1/2-
dependent signaling [5], suggesting a causal link between
decreased insulin signaling and accelerated atherosclerosis.
Genome-wide studies suggest a link between acute coro-
nary syndrome (ACS) and the 2q36-q37.3 locus, which
encompasses the insulin receptor substrate 1 (Irs1) gene [11].
Here, we analyzed the expression of Irs2, Irs1, Akt1, and Akt2
genes in MLs from patients with DM (ACS−DM+), ACS
(ACS+DM−), and ACS plus DM (ACS+DM+).
2. Materials andMethods
2.1. Study Population. Patients aged 40 to 85 years old admit-
ted to Hospital General Universitario Gregorio Maran˜on
(Madrid, Spain) and Hospital Universitario Virgen de la Vic-
toria (Ma´laga, Spain) between 2007 and 2008 were studied.
The cases (DM+ACS+) and ACS controls (DM−ACS+) were
patients admitted to the departments of cardiology of the
participant hospitals for an ACS. Non-ACS diabetic controls
(DM+ACS−) were obtained from patients admitted to
internal medicine departments or visited outpatient oﬃces
for non-CVD-related causes.
The patients were included in a prospective, hospital-
based, case-control study to compare patient diﬀerences in
the genetic expression of IRS-AKT-dependent signaling. DM
patients with ACS (ACS+DM+) were compared with age-
and sex-matched patients with DM hospitalized for a non-
CVD, who had neither prior known CVD nor evidence
of CVD according to the physician interview and physical
examination plus no evidence of abnormal electrocardio-
gram and/or ventricular dysfunction on echocardiogram
(ACS−DM+) or with ACS without DM (ACS+DM−). DM
was defined as fasting plasma glucose >126mg/dL or previ-
ously treated with insulin and/or antidiabetic drugs. ACSwas
defined as the clinical condition with a written diagnosis in
the clinical record of ACS, unstable angina, or acute myocar-
dial infarction, which prompted urgent hospitalization, and
was characterized by the following criteria: (1) chest pain or
symptom compatible with myocardial ischemia associated
with at least one of the following: (a) rise in biomarkers of
myocardial necrosis, (b) acute repolarization changes in the
ECG, or (c) angiographic evidence of coronary artery disease
and (2) absence of extreme pathophysiological condition as
a trigger, such as (a) tachycardia of any cause >120 beats per
minute, (b) severe hypotension < 80mmHg, (c) hypertensive
emergency (systolic blood pressure > 200mmHg), and (d)
severe anaemia (haemoglobin < 8 gr/dL). The study was
approved by the local ethical committees in the two hospitals,
and patients were enrolled after providing written informed
consent.
2.2. Gene Expression Analysis by Quantitative Real-Time
PCR (qPCR). Total RNA from human MLs was isolated
from 3mL of frozen blood by addition of 7.5mL RNAlater
(Ambion) and extraction with the RiboPure-Blood kit
(Ambion, AM1928). RNA purity and concentration were
determined from the A260/280 ratio. 0.5–1 μg RNA was
reverse-transcribed using the Superscript III First Strand
Synthesis Supermix (Invitrogen), and cDNAwas PCR ampli-
fied with the Platinum Quantitative PCR Supermix-UDG kit
and ROX dye (Invitrogen). qPCR reactions were run on a
7500 Fast System thermal cycler (Applied Biosystems), and
results were analyzed with the software provided by the man-
ufacturer. The following primers (Forward: Fw; Reverse: Rv)
were designed with the Primer Express program (Applied
Biosystems): Irs1: Fw-5′-CGGAGAGCGATGGCTTCTC-3′ ;
Rv 5′-GTTTGTGCATGCTCTTGGGTTT-3′; Irs2: Fw-5′-
CCGACGCCAAGCACAAGTA-3′; Rv 5′-GGCCACGGC-
GAAGTA-3′; Akt1: Fw 5′-CCGACGCCAAGCACAAGTA-
3′; Rv 5′-CGGCCACGGCGAAGTA-3′; Akt2: Fw 5′-CAA-
GGATGAAGTCGCTCACACA-3′; Rv 5′-GAACGGGTG-
CCTGGTGTTC-3′ ; Gapdh: Fw 5′-ACCACAGTCCATGCC-
ATCAC-3′; Rv 5′-TCCACCACCCTGTTGCTGTA-3′.
2.3. Statistical Analysis. qPCR data were analyzed by one-
way ANOVA. Diﬀerences in demographic and clinical char-
acteristics were analyzed by one-way ANOVA for quantitative
parameters and Chi-square test for qualitative variants, using
the SPSS program (Statistical Package for Social Sciences)
version 13.0 for Windows (SPSS Inc., Chicago, IU, USA).
Outliers were identified by Grubb’s test and eliminated.
Quantitative variables appear as means ± standard deviation
and qualitative variables as percentages. Statistical signifi-
cance was assigned at P < .05.
3. Results
The study groups consisted of 35 cases (ACS+DM+), 45
nondiabetic ACS controls (ACS+DM−), and 31 diabetic
controls without CVD (ACS−DM+). Table 1 shows the
baseline characteristics according to the study groups.
Dyslipidemia was more frequent in ACS+DM+ than
in ACS−DM+ and ACS+DM− patients (P < .007). No
diﬀerences were detected in arterial hypertension, age, sex,
body weight, or smoking among the three groups.
Previous studies showed that patients with type 2 DM
plus IR or IR alone have reduced expression of insulin
receptor (Ins-r), Irs2 and Akt2 in pancreatic β-cells, and
MLs [5, 12]. Total RNA was prepared from MLs from
patients with ACS−DM+, ACS+DM−, or ACS+DM+, and
the expression of insulin signaling genes was analyzed by
qPCR. The expression of Akt1, Irs2, and Akt2 mRNA did not
vary between the three patient groups (Figure 1). In contrast,
Irs1 transcript levels were significantly higher in MLs from
ACS+DM− (P < .005) or ACS+DM+ (P < .02) patients
than in cells from ACS−DM+ patients. No diﬀerences in
mRNA expression were observed between ACS+DM− and
ACS+DM+ patients, suggesting that increased expression of
Irs1 is associated with ACS independently of DM.
4. Discussion
Our results show that Irs1 mRNA expression in MLs from
ACS+DM− and ACS+DM+ patients is higher than in cells
from ACS−DM+patients. Previous studies in our laboratory
showed elevated Irs1 mRNA expression in MLs from predi-
abetic IR-MetS patients, who also exhibited increased CVD
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Table 1: Baseline characteristics according to study group.
ACS−DM+ ACS+DM− ACS+DM+ P value
n = 31 n = 45 n = 35
Age in years (average± SEM) 62.7± 2.0 65.1 ± 2.5 65.1 ± 1.9 .36
Sex (% male) 68.8 81.1 68.3 .36
Body weight Kg (average ± SEM) 72.8± 2.0 80.0 ± 2.9 78.1 ± 2.6 .15
Heigh cm (average± SEM) 164.8± 1.1 165.6 ± 1.7 165.8 ± 1.5 .85
Arterial hypertension (%) 62.5 54.1 73.2 .21
Dyslipidemia (%) 56.3 29.7 63.4 .007
Smoking (%) 57.4 64.9 58.5 .77
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Figure 1: mRNA expression of insulin signaling genes in MLs from patients with ACS+DM−, ACS+DM+, and ACS−DM+. Expression of
Irs1, Irs2, Akt1, and Akt2 in humanWMBCs was analyzed by qPCR. mRNA amounts were normalized to the expression ofGapdh, which did
not vary between groups, and expression levels are presented relative to the values in patients with DM without ACS (=1).
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risk [5]. These findings are consistent with genome-wide
studies that suggest linkage between ACS and the 2q36-q37.3
locus, which contains the Irs1 gene [11]. More specifically,
the IRS1 972Arg variant has also been associated with a 3-
year post-ACS mortality [13], suggesting a role of IRS1 in
ACS complications. In the present study, Irs1 mRNA levels in
ACS+DM− and ACS+DM+patients were similar, suggesting
that the presence of DM does not have an eﬀect on Irs1
expression.
Interestingly, myocardial infarction induced by artery
ligation in nondiabetic rats causes a partial impairment of
insulin response that is associated with cardiac contractile
dysfunction [14]. ACS in human patients might produce
a similar defect in insulin-mediated signaling, resulting in
a compensatory increase in Irs1 expression. The present
findings suggest that Irs1 expression levels might be a marker
of ACS; however, further studies are required to assess the
importance of increased Irs1 expression in ACS and to define
the underlying molecular mechanisms.
5. Conclusion
In the present study, we demonstrate an association between
increased Irs1 mRNA levels in human ML of patients with
ACS which is not related to DM and suggest that Irs1 levels
might be a potential marker for ACS.
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